Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice-Reference-Cited by-同舟云学术

Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice

Published:2015-07-25 Issue:11 Volume:50 Page:1145-1151
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Kai Yugo,Hikita Hayato,Tatsumi Tomohide,Nakabori Tasuku,Saito Yoshinobu,Morishita Naoki,Tanaka Satoshi,Nawa Takatoshi,Oze Tsugiko,Sakamori Ryotaro,Yakushijin Takayuki,Hiramatsu Naoki,Suemizu Hiroshi,Takehara Tetsuo

Funder

Grant-in-Aid for Research on Hepatitis from Japan Agency for Medical Research and development

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-015-1108-6.pdf

Reference20 articles.

1. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58:428–38.

2. Poole RM. Daclatasvir + asunaprevir: first global approval. Drugs. 2014;74:1559–71.

3. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–24.